Business context and reporting period
Filing identity: The supplied 10-Q is for Anzu Special Acquisition Corp I, not Envoy Medical, Inc. Investors should verify that this is the intended filing. It reports the quarter ended March 31, 2021; the company was a blank-check SPAC formed to pursue a business combination, with a stated focus on industrial technologies. It completed its IPO on March 4, 2021 and had not begun operating activities or generated operating revenue.
Financial results and liquidity
- Revenue: No operating revenue. The company reported $7,841 of trust-account interest income.
- Expenses and earnings: Formation and operating costs were $966,277; a $512,000 noncash warrant fair-value loss contributed to a net loss of $1,470,436. Class B basic and diluted loss per share was $0.14; redeemable Class A income per share rounded to $0.00.
- Cash and liquidity: At March 31, cash outside the trust was $2,154,451, working capital was $3,208,999, and trust assets were $420,007,841. Total assets were $423,313,268. The company said it believed funds outside the trust were sufficient for its search, but cautioned that higher-than-expected search and transaction costs could leave it short.
- Debt and obligations: No long-term debt or working-capital loans were outstanding. Current liabilities were $96,428. The balance sheet included a $26,772,000 warrant liability and $14,700,000 of deferred underwriting discount, payable only if a business combination is completed. Monthly affiliate administrative fees are disclosed as $40,521 in the notes and $40,251 in MD&A.
- Cash flow: Operating cash use was $1,248,975 for the period from inception through March 31. Investing cash use was $420 million, principally funds placed in the trust; financing cash provided was $423,378,426.
Material changes and unusual items
- The SPAC began the quarter with $25,000 of cash and completed its $420 million IPO during the period. The statements cover the company’s initial operating period; no directly comparable prior-year quarter is presented.
- After SEC staff guidance issued April 12, 2021, management changed warrant accounting from equity to derivative liabilities measured at fair value. The quarter-end warrant liability was $26.772 million, and the $512,000 fair-value change increased the reported loss.
- On April 14, 2021, after quarter-end, the underwriters bought 500,000 additional units and the sponsor purchased 100,000 additional private warrants; the sponsor also forfeited 1,450,000 founder shares. These events were disclosed as subsequent events, not March 31 balances.
Outlook, risks, and contingencies
- The company was evaluating potential targets but had no definitive business combination identified in the filing. It had until March 4, 2023, subject to any approved extension, to complete a combination or redeem public shares and liquidate.
- Public shareholders may redeem shares in connection with a business combination or if no combination is completed by the deadline. Warrants could expire worthless if the company liquidates.
- COVID-19 could adversely affect the company’s financial position, operations, or target search; management said the specific impact was not determinable.
- Management identified a material weakness in internal control over financial reporting related to warrant accounting; disclosure controls were therefore deemed ineffective as of March 31. Remediation was being evaluated, with no assurance it would be successful. The company also cited potential litigation or disputes related to the weakness, but reported no known such litigation as of the filing.
- The company reported no material legal proceedings outside the ordinary course and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the filing issuer: this document is for Anzu Special Acquisition Corp I, not Envoy Medical, Inc.
- Review the warrant-liability accounting correction, its earnings impact, and progress remediating the related material weakness.
- Reconcile the conflicting monthly administrative-fee amounts ($40,521 in the notes versus $40,251 in MD&A).
- Check the status and terms of any later business-combination proposal, shareholder redemptions, and the trust balance.